Neutrolis, Inc. has released positive results from the Phase 1a portion of its LIBERATE-I trial, spotlighting NTR-1011’s potential in dismantling harmful Neutrophil Extracellular Traps (NETs). This first-in-class DNASE1L3 fusion protein aims to address chronic inflammatory pathways without compromising the immune system.